EUVIMEDEUVIMED entdecken
Open Access

Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer

Stefania Morganti iD, Christopher J Gibson iD, Qingchun Jin iD, Katheryn Santos iD, Ashka Patel, Alex Wilson iD, Margaret Merrill, Julie Vincuilla, Samantha Stokes, Marla Lipsyc-Sharf iD, Tonia Parker, Tari A King und 11 weitere

Journal of Clinical Oncology · 2024-11 · 42 (31) · 3666-3679

DOI: 10.1200/jco.23.01071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2024-11. Verfasst von Stefania Morganti und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Clonal Hematopoiesis, Breast Neoplasms. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Clonal hematopoiesis of indeterminate potential (CHIP) is frequent in patients with solid tumors. Prospective data about CHIP prevalence at breast cancer diagnosis and its dynamic evolution under treatment selective pressure are limited. PATIENTS AND METHODS We performed targeted error-corrected sequencing on 614 samples from 380 patients with breast cancer. We investigated the dynamics of CHIP on prospectively collected paired samples from patients with early breast cancer (eBC) receiving chemotherapy (CT) or endocrine therapy (ET). We assessed the correlation of CHIP with survival in patients with metastatic triple-negative breast cancer (mTNBC). We estimated the risk of progression to treatment-related myeloid neoplasms (t-MN) according to the clonal hematopoiesis risk score (CHRS). In exploratory analyses, we considered clonal hematopoiesis (CH) with variant allele fraction (VAF) ≥0.005. RESULTS CHIP was identified in 15% of patients before treatment. Few CHIP emerged after treatment, and the risk of developing new mutations was similar for patients receiving CT versus ET (odds ratio [OR], 1.16; P = .820). However, CT increased the risk of developing new CH with VAF ≥0.005 (OR, 3.45; P = .002). Five TP53- mutant CH with VAF ≥0.005 emerged among patients receiving CT. Most patients had low risk of t-MN according to the CHRS score. CHIP did not correlate with survival in mTNBC. CONCLUSION CHIP is frequent in patients with breast cancer. In this study, CT did not lead to emergence of new CHIP, and most patients had low risk of developing t-MN. This finding is reassuring, given long life expectancy of patients with eBC and the association of CHIP with morbidity and mortality. However, TP53 -mutant CH with VAF ≥0.005 emerged with CT, which carries high risk of t-MN. Evolution of these small clones and their clinical significance warrant further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clonal HematopoiesisBreast NeoplasmsHumansFemaleMiddle AgedPrognosisAgedPrevalenceAdultMutationProspective StudiesTriple Negative Breast NeoplasmsAged, 80 and over

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.
  • Harvard Medical School, Boston, MA.
  • Broad Institute of MIT and Harvard, Cambridge, MA.
  • Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.
  • Clinical Operations Department, Natera Inc, Austin, TX.

ORCID-Profile: Stefania Morganti, Christopher J Gibson, Qingchun Jin, Katheryn Santos, Alex Wilson, Marla Lipsyc-Sharf, Elizabeth A Mittendorf, Giuseppe Curigliano, Daniel G Stover, Sara M Tolaney, Lachelle D Weeks, Nabihah Tayob, Nancy U Lin, Judy E Garber, Peter G Miller, Heather A Parsons

Förderung

  • NCI NIH HHS

Zitieren

APA

Morganti, S., Gibson, C. J., Jin, Q., Santos, K., Patel, A., Wilson, A., Merrill, M., Vincuilla, J., Stokes, S., Lipsyc-Sharf, M., Parker, T., King, T. A., Mittendorf, E. A., Curigliano, G., Hughes, M. E., Stover, D. G., Tolaney, S. M., Weeks, L. D., Tayob, N., …, & Parsons, H. A. (2024). Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer. Journal of Clinical Oncology, 42(31), 3666-3679. https://doi.org/10.1200/jco.23.01071

Vancouver

Morganti S, Gibson CJ, Jin Q, Santos K, Patel A, Wilson A, et al. Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer. Journal of Clinical Oncology. 2024;42(31):3666-3679. doi:10.1200/jco.23.01071

BibTeX
@article{Morganti2024,
  author = {Morganti, Stefania and Gibson, Christopher J and Jin, Qingchun and Santos, Katheryn and Patel, Ashka and Wilson, Alex and Merrill, Margaret and Vincuilla, Julie and Stokes, Samantha and Lipsyc-Sharf, Marla and Parker, Tonia and King, Tari A and Mittendorf, Elizabeth A and Curigliano, Giuseppe and Hughes, Melissa E and Stover, Daniel G and Tolaney, Sara M and Weeks, Lachelle D and Tayob, Nabihah and Lin, Nancy U and Garber, Judy E and Miller, Peter G and Parsons, Heather A},
  title = {Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {31},
  pages = {3666--3679},
  doi = {10.1200/jco.23.01071}
}
Kostenlos starten →